Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans

Diabetes. 2018 Oct;67(10):1976-1985. doi: 10.2337/db18-0451. Epub 2018 Jul 31.

Abstract

Emerging evidence supports the importance of ghrelin to defend against starvation-induced hypoglycemia. This effect may be mediated by inhibition of glucose-stimulated insulin secretion as well as reduced insulin sensitivity. However, administration of ghrelin during meal consumption also stimulates the release of glucagon-like peptide 1 (GLP-1), an incretin important in nutrient disposition. The objective of this study was to evaluate the interaction between ghrelin and GLP-1 on parameters of glucose tolerance following a mixed-nutrient meal. Fifteen healthy men and women completed the study. Each consumed a standard meal on four separate occasions with a superimposed infusion of 1) saline, 2) ghrelin, 3) the GLP-1 receptor antagonist exendin(9-39) (Ex9), or 4) combined ghrelin and Ex9. Similar to previous studies, infusion of ghrelin caused glucose intolerance, whereas Ex9 had a minimal effect. However, combined ghrelin and Ex9 resulted in greater postprandial glycemia than either alone, and this effect was associated with impaired β-cell function and decreased glucose clearance. These findings suggest that in the fed state, stimulation of GLP-1 mitigates some of the effect of ghrelin on glucose tolerance. This novel interaction between gastrointestinal hormones suggests a system that balances insulin secretion and glucose disposal in the fed and fasting states.

Trial registration: ClinicalTrials.gov NCT01729299.

Publication types

  • Clinical Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Blood Glucose / drug effects
  • Female
  • Ghrelin / pharmacology*
  • Glucagon-Like Peptide 1 / pharmacology*
  • Glucagon-Like Peptide-1 Receptor / metabolism
  • Glucose / metabolism*
  • Glucose Intolerance
  • Humans
  • Insulin / metabolism*
  • Male
  • Postprandial Period / drug effects
  • Young Adult

Substances

  • Blood Glucose
  • Ghrelin
  • Glucagon-Like Peptide-1 Receptor
  • Insulin
  • Glucagon-Like Peptide 1
  • Glucose

Associated data

  • ClinicalTrials.gov/NCT01729299